State Street Corp Acquires 4,120,685 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

State Street Corp raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 47.1% during the third quarter, HoldingsChannel reports. The fund owned 12,870,272 shares of the company’s stock after purchasing an additional 4,120,685 shares during the quarter. State Street Corp’s holdings in Recursion Pharmaceuticals were worth $84,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Axxcess Wealth Management LLC raised its holdings in Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the period. Green Alpha Advisors LLC raised its holdings in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after acquiring an additional 1,800 shares during the period. Interchange Capital Partners LLC raised its holdings in Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after acquiring an additional 2,349 shares during the period. Amalgamated Bank increased its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. increased its holdings in shares of Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 7.1 %

Shares of NASDAQ:RXRX opened at $7.44 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $15.74. The firm has a fifty day moving average of $6.76 and a 200 day moving average of $7.24. The firm has a market capitalization of $2.13 billion, a PE ratio of -4.86 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter last year, the firm posted ($0.43) earnings per share. The firm’s revenue was up 147.6% on a year-over-year basis. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total transaction of $71,200.34. Following the completion of the sale, the director now directly owns 7,098,428 shares in the company, valued at $44,152,222.16. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 107,788 shares of company stock worth $724,691 over the last three months. Company insiders own 15.75% of the company’s stock.

Analysts Set New Price Targets

RXRX has been the topic of several research analyst reports. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Finally, Jefferies Financial Group decreased their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.